Valuation: Assembly Biosciences, Inc.

Market Cap 467M 417M 389M 354M 665M 45.26B 672M 4.67B 1.83B 23B 1.75B 1.72B 73.96B P/E 2026 *
-197x
P/E 2027 * -8.41x
Enterprise Value 381M 340M 317M 288M 542M 36.88B 548M 3.81B 1.49B 18.74B 1.43B 1.4B 60.27B EV / Sales 2026 *
6x
EV / Sales 2027 * 9.98x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
10-05 Assembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver Meeting CI
10-05 Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program MT
09-21 Assembly Biosciences, Inc.(NasdaqGS:ASMB) added to S&P Biotechnology Select Industry Index CI
09-09 Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead MT
09-09 Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead DJ
09-08 Assembly Biosciences, Inc. and Gilead Sciences, Inc. Exercise U.S. Profit-Share Option for HSV Helicase-Primase Inhibitor Program CI
09-01 UBS Initiates Assembly Biosciences at Buy With $52 Price Target MT
08-21 Certain Common Stock of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Pre-Funded Warrants of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Stock Options of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Restricted Stock Units of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Performance Stock Units of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-13 Assembly Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
1 day+0.24%
1 week+0.26%
Current month-1.92%
1 month-34.69%
3 months-19.81%
6 months-21.50%
Current year-32.26%
1 week 21.8
Extreme 21.8
23.48
1 month 21.8
Extreme 21.8
35.92
Current year 21.8
Extreme 21.795
37.01
1 year 21.8
Extreme 21.795
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
40.62
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap. Importance
6/4/26 A Free

Director

8,000 0.0514%
6/4/26 A Free

Director

8,000 0.0514%
6/4/26 A Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+0.26%-9.65%+149.45% 467M
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.16%+2.68%+51.09% 58.7B
-2.39%+0.50%+3.41%+31.33% 48.36B
-5.72%-8.88%+292.33%+636.59% 43.05B
-0.07%-1.14%+28.48%+29.17% 42.48B
-4.26%-3.11%-0.99%+101.18% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-2.97%-4.99%-13.42%-15.82% 23.93B
-1.89%-8.31%-38.46%+306.24% 22.22B
Average -3.80%-2.92%+31.65%+142.75% 38.66B
Weighted average by Cap. -4.86%-1.88%+42.59%+134.49%

Financials

2026 *2027 *
Net sales 63.43M 56.64M 52.84M 48M 90.33M 6.14B 91.2M 634M 248M 3.12B 238M 233M 10.04B 34.12M 30.47M 28.42M 25.82M 48.59M 3.3B 49.06M 341M 133M 1.68B 128M 125M 5.4B
Net income 1.4M 1.25M 1.17M 1.06M 2M 136M 2.02M 14.04M 5.49M 69.06M 5.27M 5.15M 222M -56.83M -50.75M -47.35M -43.01M -80.93M -5.5B -81.72M -568M -222M -2.8B -213M -209M -9B
Net Debt -86.48M -77.23M -72.05M -65.45M -123M -8.38B -124M -865M -338M -4.26B -325M -318M -13.69B -127M -113M -106M -96.02M -181M -12.29B -182M -1.27B -496M -6.24B -476M -466M -20.08B
Projected Income Statement - Annual - Assembly Biosciences, Inc.
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
08/10/26 $22.97 +0.09% 77,536
07/10/26 $22.95 +3.47% 190,786
06/10/26 $22.18 -2.46% 349,444
05/10/26 $22.74 +0.89% 241,747
02/10/26 $22.54 -1.91% 368,313
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Assembly Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
22.95USD
Average target price
52.00USD
Spread / Average Target
+126.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Assembly Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. ASMB Stock